Proteomics International and Atturos Announcement

Diagnostic Blood Test to Predict Onset of Diabetic Kidney Disease One Step Closer to Launch Across Europe.

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a medical technology company headquartered in Perth, Australia, has announced the successful transfer of its PromarkerD technology to the laboratories of clinical diagnostics partner, Atturos. PromarkerD is a diagnostic blood test that uses a unique protein ‘fingerprint’ to provide an early detection of the onset of diabetic kidney disease. Following the transfer of the technology to Atturos the PromarkerD test is now available as a mass spectrometry laboratory developed test (MS-LDT) to licence partners in the European market.

Professor Stephen Pennington,  Founder and Chief Scientific Officer, Atturos said, “It is a significant milestone for our two pioneering companies to be expanding the use of mass spectrometry for new clinical diagnostic tests, such as PromarkerD.”

Read Full Text.

Proteomics International Laboratories Ltd Press Release.